Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes

Kazuo Nakamura, Sho Ichi Yamagishi, Hisashi Adachi, Takanori Matsui, Yayoi Kurita-Nakamura, Masayoshi Takeuchi, Hiroyoshi Inoue, Tsutomu Imaizumi

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP-1 are higher in patients with type 2 diabetes, inhibition of MCP-1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP-1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP-1 levels in type 2 diabetic patients. Methods: Eighty-six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP-1, turnour necrosis factor-* adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP-1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects. Results: Univariate regression analysis showed that serum levels of MCP-1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant. Conclusion: The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP-1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs-RAGE system may be mainly involved in the elevation of MCP-1 in type 2 diabetic patients.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalDiabetes/Metabolism Research and Reviews
Volume24
Issue number2
DOIs
Publication statusPublished - 2008 Feb
Externally publishedYes

Fingerprint

Advanced Glycosylation End Products
Chemokine CCL2
Medical problems
Type 2 Diabetes Mellitus
Blood Proteins
Atherosclerosis
Advanced Glycosylation End Product-Specific Receptor
Adiponectin
Serum
Chemokines
Regression analysis
Physical Examination
Monocytes
Blood
Necrosis
Outpatients
History
Regression Analysis
Association reactions

Keywords

  • AGEs
  • Atherosclerosis
  • Diabetes
  • MCP-1
  • sRAGE

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. / Nakamura, Kazuo; Yamagishi, Sho Ichi; Adachi, Hisashi; Matsui, Takanori; Kurita-Nakamura, Yayoi; Takeuchi, Masayoshi; Inoue, Hiroyoshi; Imaizumi, Tsutomu.

In: Diabetes/Metabolism Research and Reviews, Vol. 24, No. 2, 02.2008, p. 109-114.

Research output: Contribution to journalArticle

Nakamura, Kazuo ; Yamagishi, Sho Ichi ; Adachi, Hisashi ; Matsui, Takanori ; Kurita-Nakamura, Yayoi ; Takeuchi, Masayoshi ; Inoue, Hiroyoshi ; Imaizumi, Tsutomu. / Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. In: Diabetes/Metabolism Research and Reviews. 2008 ; Vol. 24, No. 2. pp. 109-114.
@article{cc68c4ae41ab4f4a91798ee5eddcbfaf,
title = "Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes",
abstract = "Background: Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP-1 are higher in patients with type 2 diabetes, inhibition of MCP-1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP-1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP-1 levels in type 2 diabetic patients. Methods: Eighty-six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP-1, turnour necrosis factor-* adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP-1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects. Results: Univariate regression analysis showed that serum levels of MCP-1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant. Conclusion: The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP-1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs-RAGE system may be mainly involved in the elevation of MCP-1 in type 2 diabetic patients.",
keywords = "AGEs, Atherosclerosis, Diabetes, MCP-1, sRAGE",
author = "Kazuo Nakamura and Yamagishi, {Sho Ichi} and Hisashi Adachi and Takanori Matsui and Yayoi Kurita-Nakamura and Masayoshi Takeuchi and Hiroyoshi Inoue and Tsutomu Imaizumi",
year = "2008",
month = "2",
doi = "10.1002/dmrr.766",
language = "English",
volume = "24",
pages = "109--114",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes

AU - Nakamura, Kazuo

AU - Yamagishi, Sho Ichi

AU - Adachi, Hisashi

AU - Matsui, Takanori

AU - Kurita-Nakamura, Yayoi

AU - Takeuchi, Masayoshi

AU - Inoue, Hiroyoshi

AU - Imaizumi, Tsutomu

PY - 2008/2

Y1 - 2008/2

N2 - Background: Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP-1 are higher in patients with type 2 diabetes, inhibition of MCP-1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP-1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP-1 levels in type 2 diabetic patients. Methods: Eighty-six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP-1, turnour necrosis factor-* adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP-1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects. Results: Univariate regression analysis showed that serum levels of MCP-1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant. Conclusion: The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP-1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs-RAGE system may be mainly involved in the elevation of MCP-1 in type 2 diabetic patients.

AB - Background: Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP-1 are higher in patients with type 2 diabetes, inhibition of MCP-1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP-1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP-1 levels in type 2 diabetic patients. Methods: Eighty-six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP-1, turnour necrosis factor-* adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP-1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects. Results: Univariate regression analysis showed that serum levels of MCP-1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant. Conclusion: The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP-1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs-RAGE system may be mainly involved in the elevation of MCP-1 in type 2 diabetic patients.

KW - AGEs

KW - Atherosclerosis

KW - Diabetes

KW - MCP-1

KW - sRAGE

UR - http://www.scopus.com/inward/record.url?scp=39649118422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649118422&partnerID=8YFLogxK

U2 - 10.1002/dmrr.766

DO - 10.1002/dmrr.766

M3 - Article

C2 - 17694504

AN - SCOPUS:39649118422

VL - 24

SP - 109

EP - 114

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 2

ER -